Business
Xencor to Participate at Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment
About this update from Xencor, Inc.
PASADENA, Calif. --(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen Immunology and Inflammation Virtual Summit Date: Wednesday, November 12, 2025 Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT Piper Sandler 37th Annual Healthcare Conference Date: Tuesday, December 2, 2025 Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com . Replays of the events will be available on the Xencor website for at least 30 days following the presentations. About Xencor Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20251110946225/en/ Charles Liles [email protected] (626) 737-8118 Source: Xencor, Inc.